pustular psoriasis


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to pustular psoriasis: guttate psoriasis

pus·tu·lar pso·ri·a·sis

1. an extensive exacerbation of psoriasis, with pustule formation in the normal and psoriatic skin, fever, and granulocytosis; sometimes precipitated by oral steroids; Synonym(s): generalized pustular psoriasis of Zambusch
2. a local pustular eruption of the palms and soles, occurring most commonly in a patient with psoriasis; difficult to distinguish from acrodermatitis continua.

pustular psoriasis

Etymology: L, pustula, blister; Gk, psoriasis, itch
a severe form of psoriasis consisting of bright red patches and sterile pustules all over the body. Crops of lesions lasting 4 to 7 days occur every few days in cycles over weeks or months. Recurrences are inevitable. Fever, leukocytosis, and hypoalbuminemia are associated. In rare cases, hypovolemia and kidney failure occur. Hospitalization may be necessary for fluid replacement, steroid therapy, and sedation. Compare guttate psoriasis. See also psoriasis.
enlarge picture
Pustular psoriasis

Zambusch,

Leo von, 20th century German physician.
generalized pustular psoriasis of Zambusch - an extensive exacerbation of psoriasis. Synonym(s): pustular psoriasis

psoriasis

chronic skin condition, characterized by circumscribed, discrete and confluent, crimson red, silver-scaled, plaque-like inflammatory skin lesions, affecting 2% of population; exacerbated by stress, drugs (e.g. non-steroidal anti-inflammatory drugs, beta-blockers, angiotensin-converting enzyme inhibitors, lithium, alcohol, hydroxyquinoline), streptococcal infections, and trauma (due to Koebner phenomenon); plaques show local epidermal thickening, hypervascularity, abnormality of T-lymphocyte function, proliferation and altered differentiation of keratinocytes and parakeratosis; lesions characteristically affect extensor surfaces, scalp and trunk; nails become dystrophic, showing onycholysis, subungual hyperkeratosis and thimble pitting; small joints of hands and feet may develop psoriatic arthropathy; treated by systemic cytotoxic drugs (e.g. methotrexate, ciclosporin, azathioprine, efalizumab, hydroxycarbamide) and acitretin or topical applications, e.g. emollients, for mild presentations; coal tar ointments and balms; vitamin D analogue ointment (e.g. calcipotriol); dithranol, phototherapy (using ultraviolet B), photochemotherapy (using psoralens and long-wave ultraviolet light [PUVA])
  • guttate psoriasis widely scattered, multiple psoriatic lesions; distribution resembles raindrops on a dry pavement; characteristically develops after streptococcal throat infection

  • pustular psoriasis formation of sterile 'pustules' often of plantar skin; associated with generalized psoriasis

References in periodicals archive ?
There are no trials of methotrexate efficacy for palmoplantar pustular psoriasis.
Over the next 2 years, the patient received 5 mg/kg of intravenous infliximab every 7-8 weeks; this was increased to every 6 weeks to manage a gradual return of his pustular psoriasis.
In a separate poster reported at the same meeting, a 50-year-old patient remained clear of palmoplantar pustular psoriasis 11 months after beginning treatment with efalizumab (Raptiva).
The Company's first-in-class proprietary pipeline includes ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and peanut allergy, and ANB019, an anti-IL-36 receptor antibody for the treatment of generalized pustular psoriasis.
Cassandra M, Conte E, Cortez B: Childhood pustular psoriasis elicited by the streptococcal antigen: a case report and review of the literature.
Extracutaneous manifestations of generalized pustular psoriasis are well recognized, and include arthritis and mucosal involvement.
The Company's anti-IL-36R therapeutic antibody, called ANB019, is a novel treatment for generalized pustular psoriasis (GPP), an orphan systemic inflammatory disease with high unmet medical need.
Addition of low-dose methotrexate to infliximab in the treatment of patient with severe, recalcitrant pustular psoriasis.
Commenting on the results, CEO of XOMA, John Varian said, "By the end of October, we received the initial data from all four pyodermagangrenosum patients enrolled in our pilot study, as well as data from two patients with generalized pustular psoriasis who received gevokizumab under a compassionate use protocol.